Hepatology News

[{"demo_case":false,"query":"Hepatology","message_files":[{"filename":"temp8066193139991545381_10020_2023_Article_721-.pdf","type":"document","url":"https://ai.medsci.cn/dev-api/admin-api/infra/file/4/get/3f1e4a21d8dcfcfd6559c70f14efabb2bc3f4cb17a3b320d5214974fe9b63b5f.pdf","size":2844823}],"answer":"\n\nExtracted Key Information:\n\nTitle: \nLiraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis \n\nAbstract: \nThe study investigates the impact of liraglutide on type 2 diabetes mellitus (T2DM)-associated non-alcoholic fatty liver disease (NAFLD). It highlights liraglutide's ability to improve glucose metabolism, reduce liver tissue damage, and regulate lipid metabolism through the AMPK/ACC signaling pathway. The study also explores the role of ferroptosis inhibition in these processes.\n\nKeywords: \nLiraglutide, Type 2 diabetes mellitus, Non-alcoholic fatty liver disease, Lipid peroxidation, Ferroptosis \n\nMethods: \n- Animal study using high-fat diet and streptozotocin-induced T2DM-NAFLD mouse models. \n- RNA-seq analysis for liver gene expression. \n- Histological and biochemical analyses for liver damage and lipid accumulation. \n- In vitro studies on liver cell lines to explore ferroptosis mechanisms. \n\nResults: \n- Liraglutide improved glucose tolerance, reduced fasting blood glucose, and alleviated insulin resistance in T2DM mice. \n- It reduced liver damage and lipid accumulation, as evidenced by histological and biochemical markers. \n- Transcriptomic analysis revealed liraglutide's regulation of lipid metabolism-related genes via AMPK/ACC signaling. \n- Liraglutide inhibited ferroptosis in vitro and in vivo, with AMPK activation playing a key role. \n\nConclusions: \nLiraglutide ameliorates T2DM-associated NAFLD by activating AMPK/ACC signaling and inhibiting ferroptosis, offering a potential therapeutic avenue for managing this condition.\n\nFunding: \nThe study was supported by grants from the National Natural Science Foundation of China and other institutional funding sources.\n\nPreliminary Classification: \nThe document is a research article with a clear structure, including abstract, introduction, methods, results, and discussion. It is intended for journal publication, as indicated by its submission to "Molecular Medicine."\n\nExpected Goal: \nThe goal is likely to publish this research article in a scientific journal, as it is already formatted for submission and includes detailed experimental results and analyses.\n\n---\n\nIn summary, the requirement is classified as "article review". \n\nPlease confirm if this classification aligns with your expectations. If not, kindly provide additional details or clarify your requirements.\n\nThe classification scientist determines that your research type is:\nTranslational Medicine Research\nTranslational Medicine experts are currently reviewing.\n\n### Assessment Process for Matching the Study to the Category of "转化医学研究"\n\n#### 1. Identifying Key Elements of Conversion Medicine Research\nConversion medicine research typically focuses on translating basic biological discoveries into practical medical applications. This includes understanding the mechanisms of disease at the molecular and cellular level and developing therapeutic strategies based on these insights.\n\n#### 2. Analyzing the Abstract and Introduction\n- Abstract: The study investigates the impact of liraglutide on type 2 diabetes mellitus (T2DM)-associated non-alcoholic fatty liver disease ( (NAFLD). It highlights liraglutide's ability to improve glucose metabolism, reduce liver tissue damage, and regulate lipid metabolism through the AMPK/ACC signaling pathway.\n- Introduction: Non-alcoholic fatty liver disease (NAFLD) is one of the most common complications of type 2 diabetes mellitus (T2DM). The study aims to explore the role of liraglutide in improving T2DM-associated NAFLD and the potential molecular mechanisms involved.\n\n#### 3. Evaluating the Methods Section\n- Animal Study: The study uses high-fat diet and streptozotocin-induced T2DM-NAFLD mouse models, which is a common method in preclinical research to mimic human conditions.\n- RNA-seq Analysis: This technique is used to analyze gene expression in liver tissues, providing a comprehensive view of the molecular changes.\n- Histological and Biochemical Analyses: These methods help in evaluating liver damage and lipid accumulation, which are key indicators of NAFLD.\n- In Vitro Studies: The study also includes in vitro cell culture experiments to explore ferroptosis mechanisms, indicating a multi-faceted approach to understanding the disease.\n\n#### 4. Assessing the Results\n- Glucose Tolerance and Insulin Tolerance: Liraglutide significantly improved glucose tolerance and insulin tolerance in T2DM mice, suggesting its effectiveness in managing metabolic disorders.\n- Lipid Metabolism Regulation: Transcriptomic analysis revealed that liraglutide regulates lipid metabolism-related genes via the AMPK/ACC signaling pathway.\n- Ferroptosis Inhibition: Liraglutide inhibited ferroptosis both in vitro and in vivo, with AMPK activation playing a key role.\n\n#### 5. Reviewing the Conclusions\n- Mechanism of Action: The findings suggest that liraglutide ameliorates T2DM-associated NAFLD by activating the AMPK/ACC signaling pathway and inhibiting ferroptosis.\n- Therapeutic Potential: The study provides a new avenue for the treatment of T2DM-associated NAFLD, highlighting the potential of liraglutide as a therapeutic agent.\n\n#### 6. Considering the Keywords\n- Keywords: Liraglutide, Type 2 diabetes mellitus, Non-alcoholic fatty liver disease, Lipid peroxidation, Ferroptosis.\n - These keywords indicate that the study is focused on a specific drug (liraglutide) and its effects on a particular disease (T2DM-associated NAFLD).\n\n#### 7. Matching to the Definition of Conversion Medicine Research\n- Basic to Clinical Translation: The study starts with a basic understanding of the molecular mechanisms (AMPK/ACC signaling and ferroptosis) and translates this knowledge into a clinical application (improving T2DM-associated NAFLD).\n- Experimental Validation: The use of both animal models and in vitro cell cultures ensures that the findings are robust and can be generalized.\n- Detailed Mechanistic Insights: The study provides detailed insights into the mechanisms by which lirag\n \n\n\n\nTo the Editors of Hepatology,\n\nThis manuscript has been identified as a published article: Guo et al., Molecular Medicine (2023) 29:132. As per the journal's policy for reviewing previously published material submitted in error, I provide the following key opinions as if it were a new submission, to guide editorial assessment.\n\n***\n\nReviewer Report\n\nManuscript ID: [Hypothetical ID]\nManuscript Title: Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis\nDate: August 1, 2025\n\n***\n\n### Phase 1: Target Journal Analysis\n\n1. Analysis of Similar Articles in Hepatology (2023-2025):\n Articles on metabolic liver disease published in Hepatology typically present a high degree of mechanistic depth. Common features include the use of multiple, advanced preclinical models (e.g., cell-type-specific knockout mice, humanized models) and direct validation using human patient cohorts and tissues. Studies often uncover novel signaling pathways or provide definitive evidence for a therapeutic target's role, moving beyond correlational findings.\n\n2. Journal Preferences and Requirements:\n * Innovation: Hepatology requires significant novelty. Studies confirming known effects of drugs in new contexts are generally not sufficient unless they reveal a fundamentally new biological mechanism with broad implications.\n * Research Depth: The journal expects rigorous and comprehensive mechanistic investigation. This includes genetic gain- and loss-of-function studies (e.g., CRISPR, shRNA, KO/KI models) to establish causality, not just pharmacological inhibition. Rescue experiments are standard.\n * Translational Relevance: A clear path to clinical application is essential. Validation of key findings in human liver tissues or well-characterized patient cohorts is a common requirement for publication.\n\n3. Assessment based on BMJ Reviewer Guidelines:\n * Importance & Originality: The topic is important, as T2DM-associated NAFLD is a major clinical challenge. The proposed mechanism linking liraglutide to ferroptosis via AMPK/ACC is of interest. However, the originality is moderate. The individual components of this pathway (liraglutide and AMPK in NAFLD; AMPK and ACC; ferroptosis in liver injury) have been previously reported. The main contribution is connecting these elements in a single pathway, but this does not represent a paradigm shift.\n * Study Design & Methodology: The design has several weaknesses for a top-tier journal. The use of an HFD/STZ mouse model is standard but does not fully replicate the pathophysiology of human NASH. A major limitation is the exclusive reliance on hepatoma cell lines (HepG2, Hep3B, PLC) for in vitro mechanistic work. These cells have aberrant metabolic and signaling pathways, making them poor surrogates for primary hepatocytes in studies of metabolism and cell death.\n * Ethics & Transparency: Animal ethics approval is documented. Data availability is "on reasonable request," which is acceptable but less robust than public deposition often encouraged by Hepatology.\n\n### Phase 2: Overall Review\n\n1. Journal Fit Analysis:\n The manuscript, in its current form, is not a suitable candidate for Hepatology. The level of mechanistic evidence does not meet the journal's standards. The reliance on cancer cell lines for in vitro validation and the absence of human sample data are significant limitations that would likely lead to rejection without review or after initial review.\n\n2. Innovation Assessment:\n The study proposes a comprehensive mechanism for liraglutide's action in T2DM-associated NAFLD. The link to ferroptosis is the most novel aspect. However, the overall story is largely an assembly of previously suggested connections rather than the discovery of a new pathway or target.\n\n3. Research Value Assessment:\n The work has value in providing a preclinical rationale for liraglutide's hepatoprotective effects and highlights ferroptosis as a process involved in T2DM-related liver injury. It provides a solid foundation for further research.\n\n4. Methodology Assessment:\n The methodology is adequate for a foundational study but lacks the depth required for Hepatology.\n * Key Weakness 1 (In Vitro Model): The use of liver cancer cell lines is a fundamental flaw for studying hepatocyte metabolism and cell death. Conclusions drawn from these models cannot be reliably extrapolated to normal liver physiology. Primary mouse or human hepatocytes would be required.\n * Key Weakness 2 (Mechanistic Gap): The study demonstrates that liraglutide activates AMPK, which phosphorylates ACC, and that an AMPK inhibitor blocks the anti-ferroptotic effect. However, it fails to establish a causal link between ACC phosphorylation and the suppression of ferroptosis. The molecular steps connecting ACC activity to the ferroptosis machinery are not investigated, leaving a critical gap in the mechanism.\n * Key Weakness 3 (Indirect vs. Direct Effects): The authors acknowledge in the discussion that GLP-1R expression is low in hepatocytes, suggesting an indirect effect of liraglutide. This is a central question that is not experimentally addressed. For a journal focused on liver pathobiology, clarifying whether the drug acts directly on hepatocytes or via extrahepatic signals is essential. Experiments using primary hepatocytes or liver-specific GLP-1R knockout models would be necessary.\n * Key Weakness 4 (Lack of Human Data): The findings are not validated in human tissues. Demonstrating that the AMPK/ACC/ferroptosis axis is active and relevant in liver samples from patients with T2DM and NAFLD would be necessary to establish clinical significance.\n\n5. Overall Recommendation:\n Reject.\n\n The study addresses an important topic and the experiments are clearly presented. However, the work does not meet the high standards of novelty and mechanistic rigor required by Hepatology. The methodological limitations, particularly the use of cancer cell lines for metabolic studies and the significant gaps in the proposed mechanism, prevent the conclusions from being definitive. To be considered for a journal of this caliber, the study would require substantial new work, including experiments in primary hepatocytes and/or genetic models, elucidation of the ACC-ferroptosis link, and validation in human samples.\n\n【--Final content--】\n\n\n lutide affects NAFLD, which can inform future clinical trials and treatments.\n\n### Conclusion\nBased on the above assessment, the study clearly aligns with the category of "转化医学研究" (translational medicine research). It demonstrates a clear path from basic biological research to the potential clinical application of liraglutide in managing T2DM-associated NAFLD. Therefore, the classification as "article review" is appropriate, but it can also be categorized more specifically as "转化医学研究" given its focus on translating molecular mechanisms into therapeutic strategies.\n\nIf you have any additional requirements or need further clarification, please let me know.This review is based on the initial assessment that the manuscript is not suitable for Hepatology and requires substantial revision before it could be considered for a specialized journal.\n\n### Reviewer Report\n\nManuscript ID: [Hypothetical ID]\nManuscript Title: Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis\nDate: August 1, 2025\n\n***\n\n### Phase 1: Target Journal Analysis\n\n1. Analysis of Similar Articles in Hepatology (2023-2025):\n Articles on metabolic liver disease published in Hepatology typically present a high degree of mechanistic depth. Common features include the use of multiple, advanced preclinical models (e.g., cell-type-specific knockout mice, humanized models) and direct validation using human patient cohorts and tissues. Studies often uncover novel signaling pathways or provide definitive evidence for a therapeutic target's role, moving beyond correlational findings.\n\n2. Journal Preferences and Requirements:\n * Innovation: Hepatology requires significant novelty. Studies confirming known effects of drugs in new contexts are generally not sufficient unless they reveal a fundamentally new biological mechanism with broad implications.\n * Research Depth: The journal expects rigorous and comprehensive mechanistic investigation. This includes genetic gain- and loss-of-function studies (e.g., CRISPR, shRNA, KO/KI models) to establish causality, not just pharmacological inhibition. Rescue experiments are standard.\n * Translational Relevance: A clear path to clinical application is essential. Validation of key findings in human liver tissues or well-characterized patient cohorts is a common requirement for publication.\n\n3. Assessment based on BMJ Reviewer Guidelines:\n * Importance & Originality: The topic is important, as T2DM-associated NAFLD is a major clinical challenge. The proposed mechanism linking liraglutide to ferroptosis via AMPK/ACC is of interest. However, the originality is moderate. The individual components of this pathway (liraglutide and AMPK in NAFLD; AMPK and ACC; ferroptosis in liver injury) have been previously reported. The main contribution is connecting these elements in a single pathway, but this does not represent a paradigm shift.\n * Study Design & Methodology: The design has several weaknesses for a top-tier journal. The use of an HFD/STZ mouse model is standard but does not fully replicate the pathophysiology of human NASH. A major limitation is the exclusive reliance on hepatoma cell lines (HepG2, Hep3B, PLC) for in vitro mechanistic work. These cells have aberrant metabolic and signaling pathways, making them poor surrogates for primary hepatocytes in studies of metabolism and cell death.\n * Ethics & Transparency: Animal ethics approval is documented. Data availability is "on reasonable request," which is acceptable but less robust than public deposition often encouraged by Hepatology.\n\n### Phase 2: Overall Review\n\n1. Journal Fit Analysis:\n The manuscript, in its current form, is not a suitable candidate for Hepatology. The level of mechanistic evidence does not meet the journal's standards. The reliance on cancer cell lines for in vitro validation and the absence of human sample data are significant limitations that would likely lead to rejection without review or after initial review.\n\n2. Innovation Assessment:\n The study proposes a comprehensive mechanism for liraglutide's action in T2DM-associated NAFLD. The link to ferroptosis is the most novel aspect. However, the overall story is largely an assembly of previously suggested connections rather than the discovery of a new pathway or target.\n\n3. Research Value Assessment:\n The work has value in providing a preclinical rationale for liraglutide's hepatoprotective effects and highlights ferroptosis as a process involved in T2DM-related liver injury. It provides a solid foundation for further research.\n\n4. Methodology Assessment:\n The methodology is adequate for a foundational study but lacks the depth required for Hepatology.\n * Key Weakness 1 (In Vitro Model): The use of liver cancer cell lines is a fundamental flaw for studying hepatocyte metabolism and cell death. Conclusions drawn from these models cannot be reliably extrapolated to normal liver physiology. Primary mouse or human hepatocytes would be required.\n * Key Weakness 2 (Mechanistic Gap): The study demonstrates that liraglutide activates AMPK, which phosphorylates ACC, and that an AMPK inhibitor blocks the anti-ferroptotic effect. However, it fails to establish a causal link between ACC phosphorylation and the suppression of ferroptosis. The molecular steps connecting ACC activity to the ferroptosis machinery are not investigated, leaving a critical gap in the mechanism.\n * Key Weakness 3 (Indirect vs. Direct Effects): The authors acknowledge in the discussion that GLP-1R expression is low in hepatocytes, suggesting an indirect effect of liraglutide. This is a central question that is not experimentally addressed. For a journal focused on liver pathobiology, clarifying whether the drug acts directly on hepatocytes or via extrahepatic signals is essential. Experiments using primary hepatocytes or liver-specific GLP-1R knockout models would be necessary.\n * Key Weakness 4 (Lack of Human Data): The findings are not validated in human tissues. Demonstrating that the AMPK/ACC/ferroptosis axis is active and relevant in liver samples from patients with T2DM and NAFLD would be necessary to establish clinical significance.\n\n5. Overall Recommendation:\n Reject.\n\n The study addresses an important topic and the experiments are clearly presented. However, the work does not meet the high standards of novelty and mechanistic rigor required by Hepatology. The methodological limitations, particularly the use of cancer cell lines for metabolic studies and the significant gaps in the proposed mechanism, prevent the conclusions from being definitive. To be considered for a journal of this caliber, the study would require substantial new work, including experiments in primary hepatocytes and/or genetic models, elucidation of the ACC-ferroptosis link, and validation in human samples.\n\n***\n\n## Phase 3: Detailed Structural Review\n\n### 1. Title\n\n* Accuracy & Conciseness: The title is accurate but slightly long. It correctly identifies the drug (Liraglutide), the condition (T2DM-associated NAFLD), and the proposed mechanism (AMPK/ACC signaling, ferroptosis).\n* Keyword Coverage: Excellent. All key concepts are included.\n* Journal Style Match: The mechanistic claim ("by activating... and inhibiting...") is strong. For Hepatology, such a definitive claim requires unequivocal evidence, which is lacking in the manuscript. A more cautious title, such as "Liraglutide... is associated with activation of AMPK/ACC signaling and inhibition of ferroptosis," would be more appropriate given the data.\n\n### 2. Abstract\n\n* Structural Integrity: The abstract follows the standard Background-Methods-Results-Conclusions structure.\n* Element Coverage:\n * Background: The background is adequate but the sentence "But the impact of liraglutide on T2DM-associated NAFLD remains unclear" is an oversimplification; prior studies exist. It should state what specific gap this study addresses (e.g., the role of ferroptosis).\n * Methods: Key methods (HFD/STZ model, RNA-seq, in vitro culture) are mentioned. However, specifying the use of hepatoma cell lines is critical for transparency.\n* Core Result Logic: The results are presented logically, moving from in vivo observations to in vitro mechanisms. The statement "ferroptosis inhibitor rather than other cell death inhibitors rescued liver cell viability" is a key finding but is based on flawed in vitro models.\n* Conclusion Support: The conclusion that liraglutide ameliorates NAFLD "possibly through" the proposed mechanism is appropriately cautious. However, the strength of the evidence does not fully support this as a primary mechanism.\n\n### 3. Introduction\n\n* Research Background: The background provides a reasonable overview of T2DM, NAFLD, AMPK, and ferroptosis. However, it could be more focused. The general descriptions of T2DM complications could be condensed.\n* Scientific Problem: The link between liraglutide's known metabolic effects and the specific cell death pathway of ferroptosis in the context of T2DM-NAFLD is established as the key knowledge gap.\n* Research Purpose: The purpose is clearly stated: to investigate the impact and molecular mechanisms of liraglutide on T2DM-associated NAFLD, with a focus on ferroptosis.\n* Innovation Statement: The novelty is implied to be the connection of liraglutide to ferroptosis via AMPK. This is moderately novel but, as stated, builds on existing literature for each component.\n\n### 4. Methods\n\n* Study Design Rationality:\n * Animal Model: The HFD/STZ model is a widely used but criticized model for T2DM-NAFLD. It primarily induces hyperglycemia via beta-cell toxicity (STZ) rather than the progressive insulin resistance seen in human T2DM. It does not typically progress to advanced fibrosis (NASH), limiting its relevance for advanced liver disease. A diet-induced obesity model (e.g., Western diet) without STZ would be more pathologically relevant.\n * Cell Model: This is the most significant weakness. The use of hepatoma cell lines (HepG2, Hep3B, PLC) for studies on metabolism and cell death is inappropriate. These cells have dysregulated growth signaling and metabolic pathways that differ substantially from primary hepatocytes. All in vitro conclusions are therefore unreliable. Experiments must be repeated in primary mouse or human hepatocytes.\n* Methodological Rigor:\n * The use of pharmacological inhibitors (Compound C, Fer-1) is insufficient to prove causality. Genetic approaches (e.g., siRNA/shRNA knockdown or CRISPR-mediated knockout of AMPK or ACC) are required to establish a definitive mechanistic link.\n * The liraglutide dose in vitro (e.g., 2.0 µM) is very high and may not be physiologically relevant. Justification for the chosen concentrations is needed.\n * The glucose concentration in vitro (100-125 mM) is supraphysiological and represents extreme glucotoxicity, which may not reflect the chronic hyperglycemia of T2DM.\n* Statistical Analysis: The methods used (t-test, ANOVA) are appropriate for the described experiments. However, sample sizes for animal studies (n=3-8 per group) are small, especially for RNA-seq (n=3). A power analysis is not mentioned but would be expected for a top-tier journal.\n* Ethical Compliance: Animal ethics approval is stated.\n\n### 5. Results\n\n* Data Integrity: The data appear complete for the experiments performed. However, key negative data or quantifications are missing. For example, in Figure 5A, the western blots for ferroptosis-related proteins are shown without quantification or statistical analysis, making the claim of "little effect" subjective.\n* Statistical Accuracy: P-values are reported, but the small sample sizes limit the statistical power and robustness of the findings.\n* Figure/Table Quality: The figures are generally clear. However, western blot images could be improved (e.g., showing molecular weight markers). In Figure 3, the heatmaps are presented, but the text only gives counts of up/down-regulated genes. More specific examples of key genes from the analysis should be highlighted in the main text.\n* Logical Presentation: The flow from systemic effects (Fig 1, 2) to transcriptomics (Fig 3) and then to in vitro mechanistic validation (Fig 4, 5) is logical. The final in vivo experiment with Fer-1 (Fig 6) provides a good concluding point, suggesting ferroptosis is a relevant therapeutic target.\n\n### 6. Discussion\n\n* Result Interpretation: The authors correctly interpret their direct findings. However, they do not sufficiently acknowledge the limitations of their models. The conclusion that liraglutide acts via AMPK/ACC to inhibit ferroptosis is overstated, as the link between ACC phosphorylation and ferroptosis suppression was not mechanistically demonstrated.\n* Comparison with Existing Research: The discussion compares findings with previous studies on liraglutide, AMPK, and ferroptosis. It correctly points out the controversy around hepatic GLP-1R expression.\n* Novelty Discussion: The novelty is framed as linking these known pathways. This is accurate.\n* Limitations Analysis: The authors acknowledge the GLP-1R expression issue as an "unanswered question." This is a critical limitation, not just an unanswered question. The fundamental weakness of using cancer cell lines is not mentioned at all, which is a major omission. The limitations of the HFD/STZ model are also not discussed.\n* Future Outlook: The suggestion to use a GLP-1R deficient mouse is appropriate and would be a necessary next step.\n\n### 7. References\n\n* Timeliness: The references include recent papers up to 2023, which is appropriate.\n* Relevance: The cited literature is relevant to the topic.\n* Formatting: The format appears consistent.\n\n### 8. Figures & Tables\n\n* Necessity: All figures and tables are necessary to support the text.\n* Clarity: Generally clear. Error bars are present.\n* Legend Integrity: Legends are mostly complete but could be more detailed. For example, the exact concentrations and treatment durations should be reiterated in every figure legend for clarity.\n* Title Accuracy: Titles are accurate.\n\n### 9. Point-by-Point Analysis of Sentences\n\nThis section highlights issues with specific sentences, including typos, clarity, and scientific phrasing. The recurring typo "Te" for "The" is noted once and applies throughout.\n\n* General: The manuscript contains a recurring typo: "Te" should be "The". This needs to be corrected globally.\n* Abstract, Sentence 4: "But the impact of liraglutide on T2DM-associated NAFLD remains unclear." - This is too general. Rephrase to be more specific about the gap, e.g., "However, the role of ferroptosis in the hepatoprotective effects of liraglutide remains to be elucidated."\n* Abstract, Sentence 5: "...investigated the impact and potential molecular mechanisms of inhibiting ferroptosis for liraglutide improves T2DM-associated NAFLD." - Awkward phrasing. Suggest: "...investigated the hepatoprotective mechanism of liraglutide in T2DM-associated NAFLD, focusing on its potential to inhibit ferroptosis."\n* Methods, Animal Study, Sentence 5: "3 days after STZ injection were considered diabetic." - Should be: "Mice were considered diabetic 3 days after STZ injection."\n* Methods, Animal Study, Sentence 6: "...liraglutide (Lira, Novo Alle, DK-2880 Bagsvaerd, Denmark) intervention group or ferrostatin-1 (Fer-1, MedChemExpress, Shanghai, China) intervention group." - These are two separate experiments. It should be clarified that two different cohorts of T2DM mice were used for the Liraglutide and Fer-1 studies.\n* Methods, Animal Study, Sentence 7: "Lira (300 mg/kg/day) was administrated three times a week for 6 weeks." - The dose unit is incorrect. It should likely be µg/kg/day, not mg/kg/day. 300 mg/kg is an extremely high dose. Please verify and correct.\n* Methods, RNA-sequencing, Sentence 6: "Genes were considered diferentially expressed when ∣log2 (fold change)∣>1.5 and P-value<0.05." - The p-value should be an adjusted p-value (FDR) for multiple comparisons in RNA-seq analysis. Please clarify if FDR was used.\n* Results, Liraglutide alleviates..., Sentence 4: "...liraglutide signifcantly reduced ALT level (Fig. 2D) of T2DM mice, but not AST level (Fig. 2E)." - The lack of effect on AST should be discussed. Does this suggest a specific type of injury is being ameliorated?\n* Results, Liraglutide alleviates..., Sentence 8: "Tese fndings prompt us to further study the underlying functional mechanisms of liraglutide." - This sentence is unnecessary filler.\n* Results, Liraglutide regulates..., Sentence 9: "Tus, we further examined the protein and activation levels of AMPK and ACC." - "Activation levels" is vague. Be specific: "phosphorylation levels".\n* Results, Liraglutide alleviates HG-induced..., Sentence 4: "...ferroptosis inhibitor Fer-1 couldn’t rescue HG-induced decreased cell viability (Fig. 4B)." - This is a confusing result. The text later argues HG sensitizes cells to ferroptosis. Why would an inhibitor not work on HG-induced death if it involves ferroptosis? This needs clarification or the experiment needs re-evaluation. The result seems to contradict the overall hypothesis.\n* Results, Liraglutide alleviates HG-induced..., Sentence 14: "Intracellular ferrous iron level (Fe2+) was measured... founding that there were no signifcant changes..." - "founding that" should be "and found". The lack of change in Fe2+ is an important negative result that challenges the canonical definition of ferroptosis induction and should be discussed more thoroughly.\n* Discussion, Sentence 10: "Tough, the mRNA and protein levels of ACC were decreased in T2DM mice liver in our study, the acivity of ACC is more crucial for its regulation of lipid metabolism." - "Tough" should be "Although". This is a key point. The data show total ACC is down, but p-ACC/ACC ratio is up with liraglutide. The interpretation should focus on the change in the proportion of active vs. inactive enzyme.\n* Discussion, Sentence 20: "Our current vivo study shows that Fer-1 almost fully reverse T2DM-induced liver damage without altering FBG." - "reverse" should be "reverses".\n* Discussion, Sentence 22: "Further the role of ferroptosis in NAFLD should be better elucidate." - Should be "The role of ferroptosis in NAFLD should be further elucidated."\n* Discussion, Sentence 25: "Surpringly, liraglutide has a similar efect with Fer-1 on ferroptotic cell death..." - "Surpringly" should be "Notably" or removed. "efect" should be "effect".\n* Conclusions, Sentence 1: "In summary, our study reveals that AMPK/ACC inhibition dramatically promotes ferroptosis in T2DM-induced NAFLD..." - The study shows an association, it does not "reveal" this with certainty due to methodological limitations. A more accurate statement would be: "Our study suggests that liraglutide may ameliorate T2DM-induced NAFLD by activating the AMPK/ACC pathway, which is associated with the inhibition of ferroptosis."\n\n### 10. Consistency/Contradiction Assessment\n\n* Introduction vs. Discussion: The background information in the Introduction is largely distinct from the interpretation in the Discussion. There is minimal repetitive overlap.\n* Contradiction: A potential contradiction exists in the Results (Section: "Liraglutide alleviates HG-induced sensitivity to ferroptotic cell death"). Figure 4B shows that Fer-1 alone does not rescue cell death from high glucose (HG), which seems to undermine the claim that HG induces ferroptosis. However, Figures 4C/D show that Fer-1 does rescue cells from the combination of HG + Erastin/RSL3. The authors interpret this as HG sensitizing cells to ferroptosis inducers rather than directly causing it. This interpretation is plausible but needs to be stated more clearly to avoid confusion. The logic is convoluted.\n\n### 11. Recommended Journals\n\nGiven that the manuscript has significant methodological flaws (inappropriate cell models, lack of genetic validation) and the novelty is moderate, it is not suitable for a top-tier hepatology or metabolism journal. Assuming no new data can be added, the following journals would be more appropriate targets as they publish solid, yet preliminary or foundational, mechanistic studies.\n\n1. PLoS ONE\n * Impact Factor (2024): 3.7\n * CAS Partition: Biology, Q3\n * JCR Partition: Q1 (Multidisciplinary Sciences)\n * Review Time: ~1-2 months\n * Reason: Publishes technically sound research regardless of perceived novelty or impact. The study's design and data would fit the journal's scope.\n\n2. Frontiers in Pharmacology\n * Impact Factor (2024): 5.6\n * CAS Partition: Pharmacology & Pharmacy, Q1\n * JCR Partition: Q1 (Pharmacology & Pharmacy)\n * Review Time: ~2-3 months\n * Reason: Focuses on drug mechanisms. The study provides a clear pharmacological story, which is a good fit. The journal is generally more accepting of studies with pharmacological inhibitors as the primary mechanistic tool. Note: While the IF is >5, this journal's scope is a very strong match, and it is more lenient on mechanistic depth than top-tier journals.\n\n3. Biomedicine & Pharmacotherapy\n * Impact Factor (2024): 7.5\n * CAS Partition: Medicine, Q1\n * JCR Partition: Q1 (Pharmacology & Pharmacy)\n * Review Time: ~1-2 months\n * Reason: Publishes research on the molecular basis of diseases and drug actions. The link between a diabetes drug and a cell death pathway in NAFLD fits well. Note: Similar to Frontiers, the IF is higher, but the scope is an excellent match and standards for mechanistic proof are less stringent than for Hepatology.\n\n4. Journal of Diabetes Research\n * Impact Factor (2024): 3.4\n * CAS Partition: Medicine, Q3\n * JCR Partition: Q3 (Endocrinology & Metabolism)\n * Review Time: ~2-3 months\n * Reason: A specialized journal where the T2DM context would be highly valued. The liver-focused mechanism would be of interest to its readership.\n\n5. Scientific Reports\n * Impact Factor (2024): 4.6\n * CAS Partition: Comprehensive Journals, Q2\n * JCR Partition: Q2 (Multidisciplinary Sciences)\n * Review Time: ~1-2 months\n * Reason: Similar to PLoS ONE, it focuses on technical soundness. The study is a good fit for this model.\n\n6. International Journal of Molecular Sciences\n * Impact Factor (2024): 5.6\n * CAS Partition: Biology, Q1\n * JCR Partition: Q1 (Biochemistry & Molecular Biology)\n * Review Time: ~1 month\n * Reason: Broad scope in molecular biology and is known for rapid publication of solid, incremental studies. The mechanistic focus of the paper fits well.\n\n### 12. User Judgment\n\nAre you satisfied with the above review comments? If so, would you like to proceed with revising the manuscript based on these suggestions? (Please answer "Yes" or ask additional personalized questions. Answering "Yes" will proceed to the revision mode).\n "}]